Weeks Of Arthritis Pain Relief
University at Buffalo scientists develop injectable hydrogel that slowly releases medication inside joints for several weeks, potentially easing symptoms for millions worldwide
Scientists at the University at Buffalo have developed an injectable hydrogel designed to keep osteoarthritis treatments inside the joint for much longer than conventional injections. The injectable hydrogel can remain inside arthritic joints for several weeks, slowly releasing medication and improving lubrication.
The University at Buffalo hydrogel platform was designed to address the problems of keeping therapeutic compounds concentrated in the joint and releasing them gradually over time. Osteoarthritis (OA) is one of the world's leading causes of chronic pain and disability. Common treatments delivered directly into joints, including analgesics, corticosteroids, and viscosupplements, can ease symptoms, but their effects are often short-lived, and they do not consistently slow the progression of the disease.
The injectable formulation begins as a liquid, allowing it to be delivered with a minimally invasive procedure, and rapidly becomes a lubricious semisolid material at body temperature. The platform combines a biocompatible polymer matrix with drug-loaded nanocarriers. The system uses materials with prior regulatory acceptance, intended to make eventual clinical translation more practical.
## What it means This development could address the challenges of osteoarthritis treatment, where common treatments have short-lived effects and do not consistently slow the progression of the disease. The ability to deliver disease-modifying drugs directly where they are needed, while limiting exposure elsewhere in the body, could make a significant difference in the treatment of osteoarthritis. As one of the world's leading causes of chronic pain and disability, any advancement in osteoarthritis treatment has the potential to improve the lives of millions of people worldwide.
## Why it matters The impact of osteoarthritis is significant, and any development that could potentially slow the progression of the disease or provide longer-lasting relief is crucial. The University at Buffalo's injectable hydrogel platform offers a promising solution to the challenges of osteoarthritis treatment, and its potential to deliver disease-modifying drugs directly where they are needed could be a game-changer in the field of osteoarthritis research.
